open access

Vol 9, No 6 (2020)
Other materials agreed with the Editors
Published online: 2021-01-12
Get Citation

How to manage the IVF during COVID-19 pandemic among diabetic females: a scientific perspective

Mahdya A Bukhari, Sarah Saud Sibai, Ahmed M El Malky
DOI: 10.5603/DK.2020.0067
·
Clinical Diabetology 2020;9(6):372-377.

open access

Vol 9, No 6 (2020)
COVID-19 AND DIABETES
Published online: 2021-01-12

Abstract

Diabetes is a challenging clinical problem facing ob-stetricians and gynecologists when it comes to in vitro fertilization and embryo transfer (IVF-ET). During the COVID-19 pandemic we are living nowadays, COVID-19 becomes a new superimposing challenge for diabetic females need IVF-ET procedures.
The persistent lock-down of diabetic health facilities already advised by numerous organizations and con-tributing to challenging diabetes treatment is harmful to the whole population and in particular to patients with infertilities. Around 0.3% of all babies born last year were conceived with IVF-ET therapies worldwide. We recommend remedies to foresee more delicate infertility cases so as to prepare for a resumption of temporarily suspended fertility treatment.. In an age of crucial challenges for our national health services, complication prevention and tension management can help competent agencies and health providers identify patients that should be preferred to begin fertility treatment in a healthy environment.
What we consider as a possible possibility is the gradual restart of IVF, which needs many measures for diabetic patients. The problem of restarting IVF installations after the current lockdown is real since each nation follows a certain recovery curve. Especially as a result of silent dissemination, attention should be provided to COVID-19 infection among patients and health-care staff after the restart of IVF therapy. 

Abstract

Diabetes is a challenging clinical problem facing ob-stetricians and gynecologists when it comes to in vitro fertilization and embryo transfer (IVF-ET). During the COVID-19 pandemic we are living nowadays, COVID-19 becomes a new superimposing challenge for diabetic females need IVF-ET procedures.
The persistent lock-down of diabetic health facilities already advised by numerous organizations and con-tributing to challenging diabetes treatment is harmful to the whole population and in particular to patients with infertilities. Around 0.3% of all babies born last year were conceived with IVF-ET therapies worldwide. We recommend remedies to foresee more delicate infertility cases so as to prepare for a resumption of temporarily suspended fertility treatment.. In an age of crucial challenges for our national health services, complication prevention and tension management can help competent agencies and health providers identify patients that should be preferred to begin fertility treatment in a healthy environment.
What we consider as a possible possibility is the gradual restart of IVF, which needs many measures for diabetic patients. The problem of restarting IVF installations after the current lockdown is real since each nation follows a certain recovery curve. Especially as a result of silent dissemination, attention should be provided to COVID-19 infection among patients and health-care staff after the restart of IVF therapy. 

Get Citation

Keywords

IVF; COVID-19; pandemic; diabetic; females

About this article
Title

How to manage the IVF during COVID-19 pandemic among diabetic females: a scientific perspective

Journal

Clinical Diabetology

Issue

Vol 9, No 6 (2020)

Article type

Other materials agreed with the Editors

Pages

372-377

Published online

2021-01-12

DOI

10.5603/DK.2020.0067

Bibliographic record

Clinical Diabetology 2020;9(6):372-377.

Keywords

IVF
COVID-19
pandemic
diabetic
females

Authors

Mahdya A Bukhari
Sarah Saud Sibai
Ahmed M El Malky

References (42)
  1. Abdi A, Jalilian M, Sarbarzeh PA, et al. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res Clin Pract. 2020; 166: 108347.
  2. Tandulwadkar SR, Lodha PA, Mangeshikar NT. Obstetric complications in women with IVF conceived pregnancies and polycystic ovarian syndrome. J Hum Reprod Sci. 2014; 7(1): 13–18.
  3. Fabregues F, Peñarrubia J. Assisted reproduction and thromboembolic risk in the COVID-19 pandemic. Reprod Biomed Online. 2020; 41(3): 361–364.
  4. Selter J, Wen T, Palmerola KL, et al. Life-threatening complications among women with severe ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 2019; 220(6): 575.e1–575.e11.
  5. Kilpatrick CR, Ratts VS, Simckes E, et al. Severe ovarian hyperstimulation syndrome in patients with autoimmune disorders: a report of two cases. J Reprod Med. 2014; 59(11-12): 591–595.
  6. Kouhkan A, Khamseh ME, Pirjani R, et al. Obstetric and perinatal outcomes of singleton pregnancies conceived via assisted reproductive technology complicated by gestational diabetes mellitus: a prospective cohort study. BMC Pregnancy Childbirth. 2018; 18(1): 495.
  7. Szymanska M, Horosz E, Szymusik I, et al. Gestational diabetes in IVF and spontaneous pregnancies. Neuro Endocrinol Lett. 2011; 32(6): 885–888.
  8. Segars J, Katler Q, McQueen DB, et al. American Society for Reproductive Medicine Coronavirus/COVID-19 Task Force. Prior and novel coronaviruses, Coronavirus Disease 2019 (COVID-19), and human reproduction: what is known? Fertil Steril. 2020; 113(6): 1140–1149.
  9. Diriba K, Awulachew E, Getu E. The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal transmission: a systematic review and meta-analysis. Eur J Med Res. 2020; 25(1): 39.
  10. Anifandis G, Messini CI, Daponte A, et al. COVID-19 and fertility: a virtual reality. Reprod Biomed Online. 2020; 41(2): 157–159.
  11. Zhu L, She ZG, Cheng Xu, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020; 31(6): 1068–1077.e3.
  12. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020; 14(4): 395–403.
  13. Tadic M, Cuspidi C, Sala C. COVID-19 and diabetes: Is there enough evidence? J Clin Hypertens (Greenwich). 2020; 22(6): 943–948.
  14. Pugliese G, Vitale M, Resi V, et al. Is diabetes mellitus a risk factor for COronaVIrus Disease 19 (COVID-19)? Acta Diabetol. 2020; 57(11): 1275–1285.
  15. Rahimi L, Malek M, Ismail-Beigi F, et al. Challenging issues in the management of cardiovascular risk factors in diabetes during the COVID-19 pandemic: a review of current literature. Adv Ther. 2020; 37(8): 3450–3462.
  16. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020; 162: 108142.
  17. Singh AK, Gupta R, Ghosh A, et al. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020; 14(4): 303–310.
  18. Unübol M, Ayhan M, Guney E. Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis. J Clin Rheumatol. 2011; 17(1): 46–47.
  19. Paengsai N, Jourdain G, Salvadori N, et al. Recommended first-line antiretroviral therapy regimens and risk of diabetes mellitus in HIV-infected adults in resource-limited settings. Open Forum Infect Dis. 2019; 6(10): ofz298.
  20. Bruno R, Sacchi P, Maiocchi L, et al. Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review. Dig Liver Dis. 2006; 38(6): 363–373.
  21. Liverpool COVID-19 interactions. https://www.covid19-druginteractions.org/ (5.05.2020).
  22. Isidori AM, Arnaldi G, Boscaro M, et al. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. J Endocrinol Invest. 2020; 43(8): 1141–1147.
  23. Thong E, Codner E, Laven J, et al. Diabetes: a metabolic and reproductive disorder in women. The Lancet Diabetes & Endocrinology. 2020; 8(2): 134–149.
  24. Swanton A, Storey L, McVeigh E, et al. IVF outcome in women with PCOS, PCO and normal ovarian morphology. Eur J Obstet Gynecol Reprod Biol. 2010; 149(1): 68–71.
  25. Li HW, Lee VC, Lau EY, et al. Cumulative live-birth rate in women with polycystic ovary syndrome or isolated polycystic ovaries undergoing in-vitro fertilisation treatment. J Assist Reprod Genet. 2014; 31(2): 205–211.
  26. Anagnostis P, Christou K, Artzouchaltzi AM, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol. 2019; 180(1): 41–50.
  27. Paschou SA, Papanas N. Type 2 Diabetes Mellitus and Menopausal Hormone Therapy: An Update. Diabetes Ther. 2019; 10(6): 2313–2320.
  28. Tang T, Glanville J, Orsi N, et al. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21(6): 1416–1425.
  29. Haas DA, Carr BR, Attia GR. Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2003; 79(3): 469–481.
  30. Harborne L, Fleming R, Lyall H, et al. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003; 361(9372): 1894–1901.
  31. Kjøtrød SB, von Düring V, Carlsen SM. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum Reprod. 2004; 19(6): 1315–1322.
  32. Mansfield R, Galea R, Brincat M, et al. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril. 2003; 79(4): 956–962.
  33. Anagnostis P, et al. Abstract 921. Presented at: European Association for the Study of Diabetes Annual Meeting; Sept. 16-20, 2019; Barcelona, Spain.
  34. Maroufizadeh S, Navid B, Alizadeh A, et al. Risk of gestational diabetes mellitus following assisted reproductive technology: systematic review and meta-analysis of 59 cohort studies. J Matern Fetal Neonatal Med. 2019 [Epub ahead of print]: 1–10.
  35. IVF, Assisted Reproduction Techiques Linked to Increased Gestational Diabetes. (n.d.). https://www.hcplive.com/view/ivf-assisted-reproduction-techiques-linked-to-increased-gestational-diabetes (18.12.2020).
  36. Requena A, Cruz M, Vergara V, et al. A picture of the covid-19 impact on IVIRMA fertility treatment clinics in Spain and Italy. Reprod Biomed Online. 2020; 41(1): 1–5.
  37. Monteleone PAa, Nakano M, Lazar V, et al. A review of initial data on pregnancy during the COVID-19 outbreak: implications for assisted reproductive treatments. JBRA Assist Reprod. 2020; 24(2): 219–225.
  38. Peyronnet V, Sibiude J, Deruelle P, et al. [SARS-CoV-2 infection during pregnancy. Information and proposal of management care. CNGOF]. Gynecol Obstet Fertil Senol. 2020; 48(5): 436–443.
  39. Blumenfeld Z. Possible impact of COVID-19 on fertility and assisted reproductive technologies. Fertil Steril. 2020; 114(1): 56–57.
  40. Zhu C, Wu J, Liang Y, et al. Fertility intentions among couples in Shanghai under COVID-19: A cross-sectional study. Int J Gynaecol Obstet. 2020 [Epub ahead of print].
  41. Juan J, Gil MM, Rong Z, et al. Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review. Ultrasound Obstet Gynecol. 2020; 56(1): 15–27.
  42. Huntley BJF, Huntley ES, Di Mascio D, et al. Rates of Maternal and Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review. Obstet Gynecol. 2020; 136(2): 303–312.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl